De-escalation of treatment - CML - Chronic Myeloid Leukemia
ARTICLES
Final results of the Destiny Study of De-escalation and Stopping treatment in chronic myeloid leukaemia
June 2018, EHA 2018
Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)
December 7, 2017, Blood
DESTINY Study: De-Escalation of TKIs Is Safe for Patients With CML
July 13, 2017, ASH Clinical News
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
July 2017, The Lancet Heamatology
TKI De-escalation Safe in Most CML Patients With Major Molecular Response
June 17, 2017, Cancer Network
Final results of the Destiny Study of De-escalation and Stopping treatment in chronic myeloid leukaemia
June 2018, EHA 2018
Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED)
December 7, 2017, Blood
DESTINY Study: De-Escalation of TKIs Is Safe for Patients With CML
July 13, 2017, ASH Clinical News
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
July 2017, The Lancet Heamatology
TKI De-escalation Safe in Most CML Patients With Major Molecular Response
June 17, 2017, Cancer Network
